Introduction: Temozolomide (TEM) is an oral drug with encouraging results in pancreatic NETs (PNETs). MGMT tumor deficiency seems to be correlated with higher treatment efficacy.
Aim(s): To assess MGMT expression and its correlation with the efficacy of TEM in pts with NETs.
Materials and methods: Inclusion of pts with well-differentiated, progressive NETs treated with TEM. Treatment efficacy was defined according to RECIST. Pts with progression or stable disease were considered non-responders. Nuclear expression of MGMT was studied by immunohistochemistry and graded according to the intensity of staining (0 to 3) and the proportion of positive cells, leading to a score comprised between 0 and 300. A score>80 was defined as high.
Conference: 9th Annual ENETS Conference (2012)
Presenting Author: Dr Olivia Hentic
To read results and conclusion, please login ...
Further abstracts you may be interested in